RxDoctor Payments Data

Christy Kinsey

Nurse Practitioner · Chattanooga, TNNPI 1083083380

Payments from drug & device makers

$2,946in general payments, 2019–2025

Across 118 payments — averaging $24.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$708
  • GSK$436
  • Regeneron Healthcare Solutions, Inc.$406
  • Pfizer$224
  • Sanofi$168
  • Takeda Pharmaceuticals U.S.A., Inc.$148
  • plus $857 from 14 others

What the payments were for

  • Food & beverage$2,946100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,946 in reported general payments places this provider in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.

See all nurse practitioner providers in Tennessee

Medicare billing

Part B allowed, 2024
$27,710
Medicare patients
194
Services billed
2,329

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Trelegy ElliptaFluticasone/Umeclidin/Vilanter47$37,020
Breztri AerosphereBudesonide/Glycopyr/Formoterol13$8,193
Advair HfaFluticasone Propion/Salmeterol16$5,625
Epinephrine23$4,111
Ipratropium Bromide48$1,822
Azelastine Hcl41$1,613
Albuterol Sulfate HfaAlbuterol Sulfate50$1,223
Montelukast Sodium100$977
Fluticasone Propionate54$863
Famotidine43$502
Levocetirizine Dihydrochloride46$384
Triamcinolone Acetonide12$148
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav13$118

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
GSKTrelegy Ellipta$436$37,02047 claims
AstraZenecaBreztri Aerosphere$708$8,19313 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 2,662 nurse practitioner providers in Tennessee.

Other nurse practitioner in Chattanooga

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →